Subject(s)
Diabetes Mellitus, Type 2 , Insulin Glargine , Humans , Hypoglycemic Agents , Insulin, Long-ActingABSTRACT
Rx-01_423 and Rx-01_667 are two members of the family of oxazolidinones that were designed using a combination of computational and medicinal chemistry and conventional biological techniques. The compounds have a two- to eightfold-improved potency over linezolid against serious gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci. This enhanced potency extends to the coverage of linezolid-resistant gram-positive microbes, especially multidrug-resistant enterococci and pneumococci. Compounds from this series expand the spectrum compared with linezolid to include fastidious gram-negative organisms like Haemophilus influenzae and Moraxella catarrhalis. Like linezolid, the Rx-01 compounds are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae.
Subject(s)
Anti-Infective Agents/pharmacology , Bacteria/drug effects , Oxazolidinones/pharmacology , Anti-Infective Agents/chemistry , Community-Acquired Infections/microbiology , Cross Infection/microbiology , Enterococcus/drug effects , Humans , Methicillin Resistance , Microbial Sensitivity Tests , Molecular Structure , Oxazolidinones/chemistry , Respiratory System/microbiology , Staphylococcus/drug effects , Staphylococcus aureus/drug effects , Streptococcus/drug effects , Streptococcus pneumoniae/drug effectsABSTRACT
Bacteria frequently attach to medical devices such as intravascular catheters by forming sessile multicellular communities known as biofilms, which can be the source of persistent infections that are recalcitrant to systemic antibiotic therapy. As a result of this persistence, a number of technologies have been developed to prevent catheter-associated biofilm formation. Whereas the most straightforward approaches focus on impregnating catheter material with classical antimicrobial agents, these approaches are not universally effective, thereby underscoring the need for more potent and more sophisticated approaches to the prevention of catheter-related biofilm infections.